{"filing":{"accession_number":"0001575872-26-000536","cik":"0001135951","ticker":"RDY","company_name":"DR REDDYS LABORATORIES LTD","form":"6-K","filing_date":"2026-07-28","report_date":"2026-07-28","primary_document":"rdy0931_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587226000536/rdy0931_6k.htm"},"events":[{"id":21285,"run_id":19188,"accession_number":"0001575872-26-000536","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This exhibit is a transcript of Dr. Reddy's Q1 FY27 earnings call conducted on July 22, 2026, furnished pursuant to SEBI Regulation 30. The document contains detailed financial results (consolidated revenues of ₹8,071 crores / US$853 million, EBITDA margin of 12.5%, profit after tax of ₹443 crores / US$47 million, diluted EPS of ₹5.32) and management commentary on quarterly performance, business highlights, and strategic outlook. This is a material earnings disclosure that would affect a reasonable investor's assessment of the registrant's financial condition and operational performance.","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-07-28","form":"6-K","submitted_at":null,"items":[{"id":20891,"accession_number":"0001575872-26-000536","item_number":"EX-99.1","item_title":"rdy0931_ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a transcript of Dr. Reddy's Q1 FY27 earnings call conducted on July 22, 2026, furnished pursuant to SEBI Regulation 30. The document contains detailed financial results (consolidated revenues of ₹8,071 crores / US$853 million, EBITDA margin of 12.5%, profit after tax of ₹443 crores / US$47 million, diluted EPS of ₹5.32) and management commentary on quarterly performance, business highlights, and strategic outlook. This is a material earnings disclosure that would affect a reasonable investor's assessment of the registrant's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T10:08:33.366125+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20891,"accession_number":"0001575872-26-000536","item_number":"EX-99.1","item_title":"rdy0931_ex99-1.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a transcript of Dr. Reddy's Q1 FY27 earnings call conducted on July 22, 2026, furnished pursuant to SEBI Regulation 30. The document contains detailed financial results (consolidated revenues of ₹8,071 crores / US$853 million, EBITDA margin of 12.5%, profit after tax of ₹443 crores / US$47 million, diluted EPS of ₹5.32) and management commentary on quarterly performance, business highlights, and strategic outlook. This is a material earnings disclosure that would affect a reasonable investor's assessment of the registrant's financial condition and operational performance.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-29T10:08:33.366125+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-07-28"}]}